Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phospholipids for liver function

This article was originally published in The Tan Sheet

Executive Summary

A new product from Jarrow Formulas promises to deliver powerful antioxidant activity to liver cells and protect them against glutathione loss. PolyPC, for liver and gastric support, contains polyunsaturated phosphatidylcholines, more unsaturated than endogenous phosphatidylcholines. "PolyPC is highly absorbed via the lymph [system] and circulation and concentrates in hepatocyte (liver cell) membranes," the company claims. "High concentrations of unsaturated phospholipids, such as PolyPC, have been shown to increase the activity of enzymes involved in lipid metabolism." Intended for use in tandem with Jarrow's other liver support formulas, a 60-count bottle retails for $39.95...

You may also be interested in...



UCB And Microsoft Expand AI Tie-Up Beyond COVID-19

Two European pharmaceutical companies, UCB and Merck KGaA, are exploring artificial intelligence in different ways, the first for drug discovery and the second on a fundamental level.

UK: Commercial Framework Sheds Light On Working With NHS And NICE

The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.

Coherus Aiming For More Than 10% Slice Of US Adalimumab Market

Coherus BioSciences is aiming to translate the success of its comprehensive biosimilar pegfilgrastim strategy to adalimumab, with plans to capture at least 10% of the US market upon formation in 2023. Management summarized the firm’s expectations during the company’s fourth-quarter earnings call, which revealed a downturn in pegfilgrastim sales and profitability.

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel